| Sep 23 |
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib and Successful FDA Type C Meeting on Registrational Trial Design for Regulatory Approval in Neoadjuvant Uveal Melanoma
|
| Sep 22 |
IDEAYA Announces Webcast to Report Interim Phase 2 Data for Darovasertib and Regulatory Update from FDA Type C Meeting in Neoadjuvant Uveal Melanoma on Monday, September 23, 2024
|
| Sep 20 |
Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success
|
| Sep 18 |
IDEAYA Biosciences Appoints Douglas B. Snyder as Senior Vice President, General Counsel
|
| Aug 26 |
IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 11 |
News Flash: 13 Analysts Think IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Earnings Are Under Threat
|
| Aug 8 |
IDEAYA Biosciences First Half 2024 Earnings: US$1.21 loss per share (vs US$0.98 loss in 1H 2023)
|
| Aug 6 |
IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
|
| Aug 1 |
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
|
| Jul 31 |
IDEAYA in license agreement with Biocytogen for antibody drug conjugate program
|
